Immix Biopharma Ownership
| IMMX Stock | USD 1.82 0.13 6.67% |
Immix |
Immix Stock Ownership Analysis
About 40.0% of the company shares are held by company insiders. The book value of Immix Biopharma was currently reported as 0.64. The company recorded a loss per share of 0.84. Immix Biopharma had not issued any dividends in recent years. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company was incorporated in 2012 and is headquartered in Los Angeles, California. Immix Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people. To learn more about Immix Biopharma call the company at 310 651 8041 or check out https://www.immixbio.com.Besides selling stocks to institutional investors, Immix Biopharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Immix Biopharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Immix Biopharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Immix Biopharma Quarterly Liabilities And Stockholders Equity |
|
About 40.0% of Immix Biopharma are currently held by insiders. Unlike Immix Biopharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Immix Biopharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Immix Biopharma's insider trades
Immix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immix Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immix Biopharma backward and forwards among themselves. Immix Biopharma's institutional investor refers to the entity that pools money to purchase Immix Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jane Street Group Llc | 2024-12-31 | 17.5 K | Sbi Securities Co Ltd | 2024-12-31 | 17.5 K | Ubs Group Ag | 2024-12-31 | 14.2 K | Blackrock Inc | 2024-12-31 | 14.1 K | The Colony Group Llc | 2024-12-31 | 11.9 K | Royal Bank Of Canada | 2024-12-31 | 2 K | Tortoise Investment Management, Llc | 2024-12-31 | 1.3 K | Wells Fargo & Co | 2024-12-31 | 330 | Tower Research Capital Llc | 2024-12-31 | 181 | Bleichroeder Lp | 2024-12-31 | 850 K | Cable Car Capital Llc | 2024-12-31 | 796.1 K |
Immix Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immix Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immix Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immix Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immix Biopharma Outstanding Bonds
Immix Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immix Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immix bonds can be classified according to their maturity, which is the date when Immix Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.